Ø
Ø
Ø
Ø Wholly Owned Subsidiary SeraLabs® Introduces
Nutri-Strips™, a new Oral Thin Film Strip Technology for Sleep Aid and Immunity
Applications.
CURE Pharmaceutical (OTCQB: CURR)
is a fully integrated and progressive drug delivery company. The CURR team
has extensive experience formulating and manufacturing OTC products,
pharmaceuticals, and veterinary medications placing quality and service as its
top priorities, earning the trust and respect of customers worldwide.
CURR is the pioneering developer of CUREform™, a
patented drug delivery platform that offers a number of unique
immediate-release and controlled-release drug delivery technologies designed to
improve drug efficacy, safety, and patient experience for a wide range of
active ingredients. CURR delivery technologies include CUREfilm®, an
advanced oral thin film; and CUREdrops™, an emulsion technology that can be
incorporated into different dosage forms (film, tincture, beverages, etc.),
among others. The CURR proprietary clinical pipeline includes
CUREfilm®Blue (sildenafil to treat erectile dysfunction), and CUREfilm®Canna
(THC and CBD).
As a vertically integrated
company, CURR operates a 25,000 square foot, FDA-registered, NSF® and
cGMP-certified manufacturing facility enabling it to partner with
pharmaceutical and wellness companies worldwide for private and white-labeled
production. CURR currently has partnerships in the U.S., China, Mexico,
Canada, Israel, and other markets in Europe.
Ø
On November 2nd CURR
announced it had received the first tranche of $4 million in a committed
financing of $10 million, after original issue discounts, through the issuance
of convertible notes. Axiom Capital
Management, Inc. acted as the sole placement agent in the transaction. CURR
may repay the obligations of the notes in cash only, or the notes may be
converted upon election of the investor at a fixed price of $1.32 per share
subject to certain adjustments.
This financing will enable CURR
to achieve a number of key company goals and sets the stage for making 2021 a
breakout year for the company. CURR has already set in motion the steps
needed for progress in two key areas: driving strong sales growth of newly
acquired Sera Labs, and advancing its clinical pharmaceutical pipeline,
particularly the lead clinical development program for the CURR high
value ED treatment, CUREfilm Blue™.
Ø
On October 29th CURR
announced its wholly owned subsidiary Sera Labs was launching the
Nutri-Strips brand with a multi-channel advertising and marketing strategy
beginning initially with “Sleep A.S.A.P.™,” which offers a fast-acting,
drug-free solution to America’s sleep problem.
CURR has developed a broad platform of formulations
that offer targeted dosing including patented and advanced oral thin film strip
technology, which Sera Labs has branded RAD3 --
for Rapid Activation Delivery and which it is using to deliver
novel vitamins and supplements. CURR
Nutri-Strips are administered and activate directly on the tongue, allowing for
rapid delivery. This means there is no need for water, chewing or struggling to
swallow pills. The strips are formulated by utilizing proprietary organic
polymers that trap the active ingredients in a liquid matrix which is then
cured into the Nutri-Strips.
Millions of American’s have
trouble sleeping; according to BCC research, with $52 billion being spent
annually on sleep products with Sleep A.S.A.P. as the drug free alternative to
sleeping pills. CURR scientists developed this proprietary formulation
for sleep by blending five of the most powerful sleep ingredients into one dose
to help you get to sleep and stay asleep.
CURR is also launching ImmunD3™ to
supercharge the immune system (with a once-a-week 40,000IU dose of Vitamin
D3), EnergY™ to enhance performance and mental focus,
and RecoverB™ for electrolyte and muscle recovery. Additionally,
three exciting new line extensions are set to launch in the first quarter of
2021. The brand has already begun an aggressive Q4 digital, print and Sirius
radio campaign and will have a national TV broadcast campaign starting Q1 2021
to create the world’s most impactful oral thin strip nutraceutical brand.
The company’s recent
acquisition by of Sera Labs was fueled largely to help commercialize
Nutri-Strip. CURR management expects to see a steep sales trajectory as
of a result of its extensive marketing, brand penetration and education
campaigns. Now, more than ever consumers are hyper focused on their health and
pocketbook and Nutri-Strips solves this problem by offering maximum potency of
essential vitamins and supplements while not breaking the bank.
The CURR Nutri-Strip
line is non-addictive, has no side effects and is created by top formulation
scientists. Each strip is hermetically sealed in airtight, grab-and-go
packaging to eliminate chemical and structural breakdown and provide superior
potency. Most recently, Nutri-Strip was touted at a prominent virtual industry trade
show for buyers in retail as the most innovative line in the supplement
category seen in years.
For more information on CURE
Pharmaceutical (OTCQB: CURR) visit:
###
